CLINIC GUIDE • PROGRAM OVERVIEW
Understanding
Regenerative
Options
A clear, clinic-facing breakdown of three categories — what they are, where they fit, and how to position scope, documentation, and patient expectations with disciplined language.
Educational content only. Use is determined by the treating provider, intended context, and clinic protocols.
Topical adjunct categories are for cosmetic use on intact skin only and are not for injection/IV/systemic use.
Clinical Summaries (Pilot Series)
Regenerative ECM Case Studies
Expandable, clinic‑ready summaries you can share with patients. These are small pilot series (n=3 each) with 8‑week follow‑up. They indicate short‑term safety and symptomatic improvement; larger controlled studies are needed to confirm efficacy.
Back
Safety & Early Efficacy of Perinatal‑Derived ECM for Lumbar Back Pain (n=3, 8 weeks)
8→4VAS (Pt 1, age 55)
6→2VAS (Pt 2, age 48)
7→3VAS (Pt 3, age 62)
What was done
Adults (35–70) with chronic lumbar pain >6 months and degenerative findings received a single 3 mL perinatal‑derived ECM injection into the paraspinal musculature under ultrasound guidance. Standard sterile technique and brief observation were used. Aftercare advised temporary activity modification and avoidance of NSAIDs/alcohol for 72 hours.
Outcomes at 8 weeks
| Participant | Baseline VAS | 8‑Week VAS | Reported Functional Change | Satisfaction |
|---|---|---|---|---|
| 55 y/o | 8 | 4 | Improved mobility; less morning stiffness | Very satisfied |
| 48 y/o | 6 | 2 | Better sitting tolerance; return to light exercise | Very satisfied |
| 62 y/o | 7 | 3 | Improved daily function; reduced end‑of‑day pain | Satisfied |
Why it may help
Perinatal‑derived ECM provides biologic scaffolding and bioactive signaling that may support tissue repair, modulate inflammation, and encourage angiogenesis, potentially improving the local environment for healing.
Potential adjacent applications (clinical context)
Facet‑related pain
Discogenic pain (non‑surgical)
Sacroiliac region symptoms
Paraspinal myofascial pain
These are clinical contexts where similar mechanisms may be explored. Evidence is preliminary; patient selection and imaging correlation are important.
No adverse events were observed in this 3‑participant series through 8 weeks; findings are preliminary and hypothesis‑generating.
Knee
Perinatal‑Derived ECM Combination for Knee OA (EXO‑MOVE + ECM, n=3, 8 weeks)
7→3VAS (Pt 1, KL III)
6→2VAS (Pt 2, KL II)
8→4VAS (Pt 3, KL II)
What was done
Adults 40–65 with symptomatic, radiographically confirmed Kellgren–Lawrence grade II–III OA received a single 2 mL ultrasound‑guided intra‑articular injection combining two perinatal‑derived ECM preparations. Aftercare included reduced knee loading for 2–3 days.
Outcomes at 8 weeks
| Participant | KL Grade | Baseline VAS | 8‑Week VAS | Reported Functional Change | Satisfaction |
|---|---|---|---|---|---|
| 60 y/o | III | 7 | 3 | Longer walking distance; less stiffness; first time in years without daily pain | More than satisfied |
| 40 y/o | II | 6 | 2 | Improved stair climbing; greater daily comfort | Very satisfied |
| 65 y/o | II | 8 | 4 | Functional gains; some evening pain persisted | Very satisfied |
Why a combination?
Blending complementary ECM preparations may pair structural scaffolding with bioactive signals for cellular attachment, remodeling, and inflammation modulation inside the joint.
Potential adjacent applications (clinical context)
Meniscal degeneration (non‑surgical)
Patellofemoral pain
Post‑arthroscopy recovery adjunct
Ligamentous/soft‑tissue irritation
Contexts where joint‑level anti‑inflammatory and pro‑healing environments are clinically relevant. Evidence remains early‑stage.
No adverse events observed in this series; results suggest short‑term symptomatic benefit. Controlled trials with longer follow‑up are needed.
Full clinical write‑up (tap to open)
Shoulder
Perinatal‑Derived ECM Combination for Chronic Shoulder Pain (n=3, 8 weeks)
7→2VAS (Pt 1)
6→3VAS (Pt 2)
8→2VAS (Pt 3)
What was done
Adults 35–70 with chronic shoulder pain (>6 months) and degenerative/inflammatory findings received a single 2 mL ultrasound‑guided injection combining intra‑articular and peri‑articular placement. Overhead activity was limited for 2–3 days post‑procedure.
Outcomes at 8 weeks
| Participant | Baseline VAS | 8‑Week VAS | Reported Functional Change | Satisfaction |
|---|---|---|---|---|
| 50 y/o | 7 | 2 | Improved mobility; less night pain | Very satisfied |
| 44 y/o | 6 | 3 | Better overhead tolerance; decreased stiffness | Very satisfied |
| 61 y/o | 8 | 2 | Improved daily function; mild exertional pain remains | Satisfied |
Why it may help
ECM‑based biologics may support rotator‑cuff and capsular tissue environments via scaffolding for cell attachment, pro‑angiogenic signaling, and inflammation modulation.
Potential adjacent applications (clinical context)
Rotator cuff tendinopathy
Adhesive capsulitis (frozen shoulder)
AC‑joint irritation
Biceps tendon symptoms
Use‑cases where peri‑tendinous and capsular environments are targeted. Evidence base is evolving; individualized assessment is essential.
Across three participants, pain reductions and ROM/function gains were reported by 8 weeks with no adverse events noted.
Full clinical write‑up (tap to open)
What to know before you decide
- These are small case groups (3 people each) without comparison groups. They are early snapshots to guide discussion—not final proof.
- Fit matters. Imaging, your exam, and your goals help decide if this makes sense for you.
- Expect brief soreness or swelling for a day or two. Avoid NSAIDs and alcohol for ~72 hours unless your clinician says otherwise.
- Results vary. Some people feel better quickly; others need more time or a different plan.
This overview is educational and not medical advice. Please talk with your clinician to decide what’s right for you.
Post-Thaw Viability & Cell Count Integrity
Regenerative biologic products are commonly cryopreserved for transport and storage before clinical use. While freezing allows cells to be preserved, the freeze-thaw process can affect cell integrity and function. For that reason, one of the most important quality indicators is not the number of cells originally frozen, but the number of cells that remain viable after thawing.
Cell viability refers to the percentage of living, functional cells present after the thaw process. Only living cells are capable of participating in biological signaling processes that may influence tissue environments. Understanding this concept is essential when evaluating regenerative products.
Why Post-Thaw Viability Matters
Higher Viability
- Greater proportion of living cells
- Cells capable of biological signaling
- More consistent product performance
Low Viability
- Higher percentage of non-viable cells
- Limited biological activity
- Potential for cellular debris
Viability is often measured through laboratory methods such as flow cytometry or viability staining. These tests help determine the percentage of living cells present after thawing.
Common Issues with Cell Count Claims
Cell counts listed in marketing materials may not always reflect the number of living cells actually delivered during treatment. In some cases, the reported count may include non-viable cells or other cell types that do not contribute to regenerative signaling.
- Counts that include both living and dead cells
- Numbers that include unrelated cell populations
- Missing documentation verifying the testing method
- Only reporting pre-freeze cell counts rather than post-thaw viability
For this reason, post-thaw testing is often considered one of the most meaningful indicators of product quality.
Documentation Clinics Often Review
| Documentation | Purpose |
|---|---|
| Post-thaw viability testing | Shows percentage of living cells after thaw |
| Cell identity markers | Confirms the types of cells present |
| Cryopreservation protocols | Describes how cells are frozen and preserved |
| Donor eligibility screening | Verifies safety and sourcing documentation |
| Laboratory quality oversight | Confirms quality systems in product preparation |
Key Takeaways
- Post-thaw viability is an important measure of biologic product quality.
- The number of cells originally frozen may differ from the number that remain viable.
- Documentation and testing transparency help clinicians evaluate regenerative materials.
- Understanding viability helps providers make informed decisions when reviewing biologic therapies.
This material is provided for educational purposes only and does not constitute medical advice. Information presented is intended to help clinicians and readers understand general concepts related to biologic product quality and regenerative medicine research.
Explore More Across OriGen Clinics
Browse treatments, stem cell education, clinic resources, and the main pages across the site.
Next Step for Clinics
See If Regenerative Medicine Fits Your Clinic
Explore whether stem cell–based therapies align with your clinic’s current services, patient model, and growth goals. Start with a quick clinic fit assessment or schedule a consultation to review integration possibilities.